시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 비교리스트
세계의 이식편대숙주병(GVHD) 치료 시장 보고서(2025년)
Graft Versus Host Disease (GVHD) Treatment Global Market Report 2025
상품코드 : 1704473
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 200 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ￦ 6,242,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ￦ 9,023,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ￦ 11,803,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

이식편대숙주병(GVHD) 치료 시장 규모는 향후 몇 년 동안 강력한 성장세를 보이며 2029년까지 7.5%의 CAGR로 41억 달러 규모로 성장할 것으로 예상됩니다. 예측 기간 동안의 성장은 동종 이식 수 증가, 급성 GVHD 발생률 증가, 조혈모세포 치료율 증가, 골수 이식 수요 증가, 세계 GVHD 유병률 증가, 만성 GVHD 사례 증가, 기술 발전, 환자 수 증가 등에 기인합니다. 예측 기간 동안 주요 동향으로는 파트너십, 투자, 제품 승인, 맞춤화 등을 들 수 있습니다.

혈액 질환의 증가는 당분간 이식편대숙주병(GVHD) 치료 시장의 성장을 견인할 것으로 예상됩니다. 혈액 질환은 혈액과 그 구성 성분에 영향을 미치는 다양한 질환을 포함하며, 건강에 해로운 생활습관, 유전적 소인, 방사선, 화학제품, 오염물질과 같은 환경 독성 물질에 대한 노출과 같은 요인으로 인해 점점 더 흔해지고 있습니다. 혈액질환 환자들에게 보다 광범위한 의미를 가지며, 면역 조절 및 질병 관리 개선에 새로운 기회를 제공합니다. 예를 들어, 백혈병 림프종 협회의 2023년 보고서에 따르면, 2023년 미국에서 백혈병, 림프종, 골수종으로 인해 약 5만 7,380명이 사망할 것으로 예측됩니다. 이는 하루에 약 157명, 1시간에 6명 이상이 혈액암으로 사망하는 셈입니다. 이처럼 혈액질환의 유병률 증가는 이식편대숙주병(GVHD) 치료 시장의 원동력이 되고 있습니다.

GVHD 치료 시장의 주요 업체들은 경쟁 우위를 확보하기 위해 첨단 약물을 적극적으로 개발하고 규제 당국의 승인을 받고 있습니다. 제품 승인은 헬스케어 제품이 환자에게 제공되기 전에 안전성, 유효성, 품질에 대한 필수 기준을 충족하는지 확인하는 데 중요한 역할을 합니다. 예를 들어, 2023년 3월 미국 헬스케어 기업 Incyte Corporation은 JAK1/JAK2 억제제인 룩소리티닙 서방형(XR) 정제를 개발하여 특정 유형의 골수섬유증, 진성 다혈구증, 이식편대숙주병(GVHD) 치료제로 1일 1회 투여를 위한 식품의약품안전처(FDA)의 승인을 받았습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 - 금리, 인플레이션, 지정학, 신종 코로나바이러스 감염증, 그리고 경기회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별·국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 개요

제31장 기타 주요 기업과 혁신적 기업

제32장 세계의 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병

제34장 최근의 시장 동향

제35장 시장 잠재력이 높은 국가, 부문, 전략

제36장 부록

ksm
영문 목차

영문목차

Graft versus host disease (GVHD) treatment encompasses a range of medical interventions designed to manage or mitigate the complications stemming from GVHD, a condition wherein transplanted donor cells attack the recipient's tissues. These treatments are employed to address the ramifications of GVHD, a disease characterized by the recipient's tissues being targeted by transplanted donor cells.

The primary product types utilized in graft versus host disease (GVHD) treatment include corticosteroids, monoclonal antibodies, immunosuppressants, among others. Corticosteroids are a class of steroid hormones produced in the adrenal cortex of vertebrates, as well as synthetic analogues of these hormones. GVHD treatment addresses various disease types such as acute GVHD, prophylaxis GVHD, and chronic GVHD. These treatments are utilized by diverse end users including hospital pharmacies, retail pharmacies, and online pharmacies.

The graft versus host disease (GVHD) treatment market research report is one of a series of new reports from The Business Research Company that provides graft versus host disease (GVHD) treatment market statistics, including graft versus host disease (GVHD) treatment industry global market size, regional shares, competitors with a graft versus host disease (GVHD) treatment market share, detailed graft versus host disease (GVHD) treatment market segments, market trends, and opportunities, and any further data you may need to thrive in the graft versus host disease (GVHD) treatment industry. This graft versus host disease (GVHD) treatment research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The graft versus host disease (GVHD) treatment market size has grown strongly in recent years. It will grow from $2.85 billion in 2024 to $3.07 billion in 2025 at a compound annual growth rate (CAGR) of 7.7%. The growth in the historic period can be attributed to increase in number of allogeneic transplantations, growing incidence of acute GVHD, increasing the rate of hematopoietic stem cell treatment, rising demand for bone marrow transplants, rising prevalence of GVHD worldwide, increase in chronic GVHD cases, advancements in technology, rise in patient population.

The graft versus host disease (GVHD) treatment market size is expected to see strong growth in the next few years. It will grow to $4.1 billion in 2029 at a compound annual growth rate (CAGR) of 7.5%. The growth in the forecast period can be attributed to Increase in the number of allogeneic transplantations, growing incidence of acute GVHD, increasing the rate of hematopoietic stem cell treatment, rising demand for bone marrow transplants, rising prevalence of GVHD worldwide, increase in chronic GVHD cases, advancements in technology, rise in the patient population. Major trends in the forecast period include partnerships, investment, product approvals, and customizations.

The anticipated rise in hematological disorders is expected to drive the growth of the graft versus host disease (GVHD) treatment market in the foreseeable future. Hematological disorders, which encompass various conditions affecting the blood and its components, are becoming more prevalent due to factors such as unhealthy lifestyle habits, genetic predisposition, and exposure to environmental toxins such as radiation, chemicals, and pollutants. Treatment strategies developed for managing GVHD can have broader implications for patients with hematological disorders, presenting new opportunities for immune modulation and improved disease management. For example, according to the Leukemia & Lymphoma Society's 2023 report, leukemia, lymphoma, and myeloma are projected to cause the deaths of approximately 57,380 people in the US in 2023. This equates to roughly 157 individuals per day or more than six deaths every hour from blood cancer. Thus, the increasing prevalence of hematological disorders is a driving force behind the graft versus host disease (GVHD) treatment market.

Key players in the GVHD treatment market are actively developing advanced drugs and seeking regulatory approval to gain a competitive edge. Product approvals play a crucial role in ensuring that healthcare products meet the necessary standards for safety, efficacy, and quality before they are made available to patients. For instance, in March 2023, Incyte Corporation, a US-based healthcare company, developed ruxolitinib extended-release (XR) tablets, a JAK1/JAK2 inhibitor, which received approval from the Food and Drug Administration (FDA) for once-daily use in treating specific types of myelofibrosis, polycythemia vera, and graft-versus-host disease (GVHD).

In March 2024, Lonza Group Ltd, a Switzerland-based healthcare manufacturing company, acquired Roche's biologics manufacturing site for $1.2 billion. With this acquisition, Lonza aims to expand its portfolio by incorporating Roche's expertise in the treatment of graft-versus-host disease (GVHD). F. Hoffmann-La Roche AG, a Switzerland-based company, specializes in providing treatment options for GVHD, a condition that can occur after stem cell or bone marrow transplants.

Major companies operating in the graft versus host disease (GVHD) treatment market are Pfizer Inc., Johnson & Johnson Services Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Sanofi SA, Novartis AG, Bristol Myers Squibb, AstraZeneca, Abbott Laboratories, GlaxoSmithKline plc, Eli Lilly And Company, Novo Nordisk A/S, Takeda Pharmaceutical Company Limited, Gilead Sciences Inc., Merck KGaA, Teva Pharmaceutical Industries Ltd., Biogen Inc., Astellas Pharma Inc., Jazz Pharmaceuticals plc, Allergan plc, Incyte Corporation, Mallinckrodt Pharmaceuticals, Genzyme Corporation, Kiadis Pharma, Neovii Pharmaceuticals AG, ElsaLys Biotech SA, Mesoblast Ltd., Soligenix

North America was the largest region in the graft versus host disease (GVHD) treatment market in 2024. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the graft versus host disease (GVHD) treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the graft versus host disease (GVHD) treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The graft versus host disease (GVHD) treatment market includes revenues earned by entities by immunosuppressive medications, clinical trials, specialized therapies and stem cell transplantation. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Graft Versus Host Disease (GVHD) Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on graft versus host disease (gvhd) treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for graft versus host disease (gvhd) treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The graft versus host disease (gvhd) treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. Graft Versus Host Disease (GVHD) Treatment Market Characteristics

3. Graft Versus Host Disease (GVHD) Treatment Market Trends And Strategies

4. Graft Versus Host Disease (GVHD) Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Graft Versus Host Disease (GVHD) Treatment Growth Analysis And Strategic Analysis Framework

6. Graft Versus Host Disease (GVHD) Treatment Market Segmentation

7. Graft Versus Host Disease (GVHD) Treatment Market Regional And Country Analysis

8. Asia-Pacific Graft Versus Host Disease (GVHD) Treatment Market

9. China Graft Versus Host Disease (GVHD) Treatment Market

10. India Graft Versus Host Disease (GVHD) Treatment Market

11. Japan Graft Versus Host Disease (GVHD) Treatment Market

12. Australia Graft Versus Host Disease (GVHD) Treatment Market

13. Indonesia Graft Versus Host Disease (GVHD) Treatment Market

14. South Korea Graft Versus Host Disease (GVHD) Treatment Market

15. Western Europe Graft Versus Host Disease (GVHD) Treatment Market

16. UK Graft Versus Host Disease (GVHD) Treatment Market

17. Germany Graft Versus Host Disease (GVHD) Treatment Market

18. France Graft Versus Host Disease (GVHD) Treatment Market

19. Italy Graft Versus Host Disease (GVHD) Treatment Market

20. Spain Graft Versus Host Disease (GVHD) Treatment Market

21. Eastern Europe Graft Versus Host Disease (GVHD) Treatment Market

22. Russia Graft Versus Host Disease (GVHD) Treatment Market

23. North America Graft Versus Host Disease (GVHD) Treatment Market

24. USA Graft Versus Host Disease (GVHD) Treatment Market

25. Canada Graft Versus Host Disease (GVHD) Treatment Market

26. South America Graft Versus Host Disease (GVHD) Treatment Market

27. Brazil Graft Versus Host Disease (GVHD) Treatment Market

28. Middle East Graft Versus Host Disease (GVHD) Treatment Market

29. Africa Graft Versus Host Disease (GVHD) Treatment Market

30. Graft Versus Host Disease (GVHD) Treatment Market Competitive Landscape And Company Profiles

31. Graft Versus Host Disease (GVHD) Treatment Market Other Major And Innovative Companies

32. Global Graft Versus Host Disease (GVHD) Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Graft Versus Host Disease (GVHD) Treatment Market

34. Recent Developments In The Graft Versus Host Disease (GVHD) Treatment Market

35. Graft Versus Host Disease (GVHD) Treatment Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기